Lung Ultrasound in the Early Detection of Postoperative Pulmonary Complications After Esophagectomy (OESOLUS)

January 13, 2026 updated by: University Hospital, Lille

Lung Ultrasound in the Early Detection of Postoperative Pulmonary Complications After Esophagectomy: A Prospective Observational Study

The perioperative management of esophageal cancer has evolved considerably in recent years.

Over the last 30 years, postoperative mortality has been steadily decreasing. However, respiratory morbidity remains high (30-40%). This is due to the procedure itself requiring a thoracic approach and intraoperative unipulmonary ventilation. The postoperative pulmonary complications (PPCs) are multiple: bronchial congestion, atelectasis, pneumopathy, acute respiratory failure, liquid pleural effusion, pneumothorax.

In general, prevention and early treatment are aimed at limiting the evolution towards acute respiratory failure requiring ventilatory assistance.

Chest radiography is essential for the presumptive diagnosis of pneumopathy in particular, but the interpretation of the images may be difficult.

Thoracic computed tomography (CT) is the gold standard because it is sensitive and can discriminate among differential diagnoses. This is difficult to perform: it requires intra-hospital transport of patient, who is often in acute respiratory failure, and the availability of an examination area.

Lung ultrasound is used at the bedside for diagnosis of lung infection in intensive care unit. This has a sensitivity close to thoracic CT and has the advantage of being feasible at any time, does not require transport of the patient and is not irradiating.

Lung ultrasound allows early detection of the need for ventilatory support in postoperative major abdominal surgery . In addition, the sensitivity of lung ultrasound is close to that of CT, allowing this examination to be relied upon.

The main objective of the study is to determine the role of lung ultrasound (LUS) in the prediction of postoperative pulmonary complications within one hour after extubation. The secondary objectives are to determine the performance of lung and diaphragmatic ultrasound (DUS) on postoperative day 1 and to establish a predictive model integrating LUS, DUS, and clinical variables to improve early identification of patients at risk of postoperative pulmonary complications.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

274

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lille, France
        • Hop Claude Huriez Chu Lille

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Prospective cohort study of esophagectomy patients in a tertiary hospital

Description

Inclusion Criteria:

  • Thoracic Esophagectomy

Exclusion Criteria:

  • Emphysema Death during surgery Refusal

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Area under the curve (AUC) of the Lung ultrasound score
Time Frame: at Day 0 (within 1 hour of tracheal extubation)
at Day 0 (within 1 hour of tracheal extubation)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The presence of pleural effusion at D0, D1 or D3
Time Frame: at Day 0, Day 1 and Day 3
at Day 0, Day 1 and Day 3
Diaphragmatic excursion is measured via subcostal diaphragmatic ultrasound performed during the patient's clinical examination
Time Frame: at Day 0, Day 1 and Day 3
at Day 0, Day 1 and Day 3
Complications according to the Dindo-Clavien classification
Time Frame: at Day 7
at Day 7
The presence of condensations on pleuropulmonary ultrasound in the ICU
Time Frame: at Day 0, Day 1 and Day 3
at Day 0, Day 1 and Day 3
Mortality at D30 according to the LUS score at day 0 and day 1
Time Frame: Between Day 0 et Day 30
Between Day 0 et Day 30
Correlation between the LUS score on day 0 and day 1 and the mechanical energy delivered to the lung during surgery.
Time Frame: between the day 0 and the day 1
between the day 0 and the day 1
Assess whether diaphragmatic excursion measured on day 0, day 1, ans day 3 is predictive of CPPO within 7 days post-operatively.
Time Frame: Within 7 days post-operatively.
Within 7 days post-operatively.
Evaluate whether the LUS score on day 1 correlates with PaO2/FiO2 on day 1.
Time Frame: A day 1.
A day 1.
Area under the curve (AUC) of the Lung ultrasound score at Day 1
Time Frame: Day 1
Day 1
Predictive model for postoperative pulmonary complications
Time Frame: At day 1
Establish a predictive model integrating LUS, DUS and clinical variables (age, ASA score, surgical approach)
At day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Cédric CIRENEI, MD,PhD, University Hospital, Lille

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 22, 2022

Primary Completion (Actual)

April 30, 2025

Study Completion (Actual)

April 30, 2025

Study Registration Dates

First Submitted

July 7, 2022

First Submitted That Met QC Criteria

July 7, 2022

First Posted (Actual)

July 12, 2022

Study Record Updates

Last Update Posted (Actual)

January 15, 2026

Last Update Submitted That Met QC Criteria

January 13, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Esophageal Neoplasm

Subscribe